Open for inclusion

Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphpoma

Cancer type: Lymphoma

Phase: II

Principal Investigator: Leppä Sirpa

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03293173